Objectives: Objectives are to first, update and inform stakeholders in the Medical Device and Diagnostic ecosystem on current practices involving the usage of HTA reports by procurement decision makers based on a systematic literature review conducted by MD&D SIG members, present gaps in knowledge – how procurement uses (or does not use) HTA and evidence, and contrast with current procurement practices in Europe and US. This would include similarities between hospital based HTA, Value Analysis Committees and how they compare and contrast to VBP initiatives in Europe. Secondly, engage the panelists and audience on how this interaction should evolve going forward and collect ideas and best practices from the stakeholders. This forum will leave time for open group discussion after introductory comments from the speakers.

Background: HTA for MedTech often does not lead to a funding/reimbursement mandate despite being a very robust manner of technology evaluation. When done correctly, HTA considerations include clinical, economic, and societal value to multiple stakeholder groups. There are isolated pockets where MedTech funding is attached to HTA, this is far from the norm most procurement decisions are still predominantly price driven. Initiatives such as value-based procurement, where the procurement decisions are made on clinical improvement and reduced total costs suggest HTA could be a very valuable resource for procurement decision making. We will discuss this paradigm in the context of an ISPOR MD&D SIG working group special project literature review and the future initiative to survey of HTA and procurement stakeholders.